BioXcel Therapeutics Files 8-K on Financials
Ticker: BTAI · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001720893
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: BXTL
TL;DR
BXTL filed an 8-K on 3/27/26 detailing financial results.
AI Summary
BioXcel Therapeutics, Inc. filed an 8-K on March 27, 2026, reporting on its financial condition and results of operations. The filing includes financial statements and exhibits, with the primary document being the 8-K itself in iXBRL format.
Why It Matters
This filing provides investors with an update on BioXcel Therapeutics' financial performance and condition as of March 27, 2026.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate new material events indicated.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Filer of the 8-K
- 0001720893 (company) — CIK number for BioXcel Therapeutics, Inc.
- 2026-03-27 (date) — Period of Report and Filing Date
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates Item 2.02: Results of Operations and Financial Condition, but the specific details of the results are not provided in the summary information.
What exhibits are included with this 8-K filing?
The filing includes Exhibit 99.1, which is EX-99.1, and various XBRL taxonomy extension files.
When was this 8-K filing accepted by the SEC?
The filing was accepted on March 27, 2026, at 07:21:25.
What is the CIK number for BioXcel Therapeutics, Inc.?
The CIK number for BioXcel Therapeutics, Inc. is 0001720893.
What is the business address of BioXcel Therapeutics, Inc.?
The business address is 555 LONG WHARF DRIVE NEW HAVEN CT 06511.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2026-03-27 07:21:25
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
Filing Documents
- tm269970d1_8k.htm (8-K) — 26KB
- tm269970d1_ex99-1.htm (EX-99.1) — 45KB
- 0001104659-26-035661.txt ( ) — 242KB
- btai-20260327.xsd (EX-101.SCH) — 3KB
- btai-20260327_lab.xml (EX-101.LAB) — 33KB
- btai-20260327_pre.xml (EX-101.PRE) — 22KB
- tm269970d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 27, 2026, BioXcel Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months and year ended December 31, 2025 and provided a business update. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d)Exhibits. Ex. No. Description 99.1 Press release 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 27, 2026 BIOXCEL THERAPEUTICS, INC. By: /s/ Richard Steinhart Richard Steinhart Title: Chief Financial Officer